ASH 2021 | Targeting TSLPR in Ph-like and Down syndrome-associated ALL
Sarah Tasian
• 13 Dec 2021
Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses treatment strategies for patients with Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) and Down Syndrome-associated ALL. A chimeric antigen receptor (CAR) T-cell therapy targeting thymic stromal lymphopoietin receptor (TSLPR), which is encoded by cytokine receptor-like factor 2 (CRLF2), was combined with ruxolitinib. The resulting regimen decreased the efficacy of the CAR T-cell therapy but delayed administration of ruxolitinib may beneficially reduce cytokine release syndrome (CRS) severity. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
